Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Impact of total PSA and percent free PSA in the differentiation of prostate disease: a retrospective comparative study implicating neoplastic and non-neoplastic entities.

Vezyraki P, Vlachaki A, Baltogiannis D, Batistatou A, Tsampalas S, V Simos Y, Kaltsas A, Pappas P, Dounousi E, Ragos V, Tsiambas E, Peschos D.

J BUON. 2019 Sep-Oct;24(5):2107-2113.

2.

SHARP hypofractionated stereotactic radiotherapy for localized prostate cancer: a biochemical response to treatment.

Rucinska M, Osowiecka K, Kieszkowska Grudny A, Nawrocki S.

J BUON. 2019 Sep-Oct;24(5):2099-2106.

3.

Long non-coding RNA VIM-AS1 promotes prostate cancer growth and invasion by regulating epithelial-mesenchymal transition.

Zhang Y, Zhang J, Liang S, Lang G, Liu G, Liu P, Deng X.

J BUON. 2019 Sep-Oct;24(5):2090-2098.

4.
5.

Delays in prostate cancer care within a hospital network in Victoria, Australia.

Qu LG, Nzenza T, McMillan K, Sengupta S.

ANZ J Surg. 2019 Nov 30. doi: 10.1111/ans.15554. [Epub ahead of print]

PMID:
31786815
6.

Does time interval between prostate biopsy and surgery affect outcomes of radical prostatectomy? A systematic review and meta-analysis.

Li J, Jiang Q, Li Q, Zhang Y, Gao L.

Int Urol Nephrol. 2019 Nov 30. doi: 10.1007/s11255-019-02344-6. [Epub ahead of print]

PMID:
31786703
7.

MRI-targeted biopsy for detecting prostate cancer: have the guidelines changed our practices and our prostate cancer detection rate?

Baboudjian M, Bandelier Q, Gondran-Tellier B, Abdallah R, Michel F, Sichez PC, Di-Crocco E, Akiki A, Gaillet S, Delaporte V, Andre M, Daniel L, Karsenty G, Lechevallier E, Boissier R.

Int Urol Nephrol. 2019 Nov 30. doi: 10.1007/s11255-019-02353-5. [Epub ahead of print]

PMID:
31786702
8.

Histologic characterization of the post-radiation urethral stenosis in men treated for prostate cancer.

Hughes M, Caza T, Li G, Daugherty M, Blakley S, Nikolavsky D.

World J Urol. 2019 Nov 30. doi: 10.1007/s00345-019-03031-y. [Epub ahead of print]

PMID:
31786640
9.

Prostate Cancer in Men with Treated Advanced Heart Failure: Should we keep Screening?

Lee HH, Shaw N, Mohammed S, Kowalczyk K, Stamatakis L, Krasnow RE.

Urology. 2019 Nov 28. pii: S0090-4295(19)31047-7. doi: 10.1016/j.urology.2019.11.022. [Epub ahead of print]

PMID:
31786304
10.

Second cancers in patients with locally advanced prostate cancer randomized to lifelong endocrine treatment with or without radical radiotherapy. Long term follow- up of the Scandinavian Prostate Cancer Group-7 trial.

Aksnessæther BY, Myklebust TÅ, Solberg A, Klepp OH, Skovlund E, Hoff SR, Fosså SD, Widmark A, Lund JÅ.

Int J Radiat Oncol Biol Phys. 2019 Nov 28. pii: S0360-3016(19)34066-0. doi: 10.1016/j.ijrobp.2019.11.027. [Epub ahead of print]

PMID:
31786279
11.

[Prostate MRI and screening: Practice survey with general practitioner of the "Bourgogne-Franche Comté" region].

Bardet F, Frontczak A, Schneider A, Delattre B, Kleinclauss F, Cormier L.

Prog Urol. 2019 Nov 27. pii: S1166-7087(19)30545-7. doi: 10.1016/j.purol.2019.09.010. [Epub ahead of print] French.

PMID:
31786110
12.

Circulating tumor cells in peripheral blood of pancreatic cancer patients and their prognostic role: a systematic review and meta-analysis.

Wang Y, Yu X, Hartmann D, Zhou J.

HPB (Oxford). 2019 Nov 27. pii: S1365-182X(19)33194-6. doi: 10.1016/j.hpb.2019.11.003. [Epub ahead of print] Review.

PMID:
31786054
13.

Phthalate exposure and prostate cancer in a population-based nested case-control study.

Chuang SC, Chen HC, Sun CW, Chen YA, Wang YH, Chiang CJ, Chen CC, Wang SL, Chen CJ, Hsiung CA.

Environ Res. 2019 Nov 8:108902. doi: 10.1016/j.envres.2019.108902. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center